Although not specifically approved for the treatment of bleeding peptic ulcers, proton pump inhibitors (PPIs) such as omeprazole (Losec AstraZeneca, Luton, UK) are widely used for this indication.

AstraZeneca has agreed to sell most global commercial rights to its gastro drug Losec (omeprazole) and associated brands to Germany’s Cheplapharm Arzneimittel in a deal worth up to $309 million.

Objective: To investigate the relative bioavailability and bioequivalence, in fasting and fed conditions, of repeated doses of two omeprazole enteric-coated formulations in healthy volunteers.